<SEC-DOCUMENT>0001453687-21-000155.txt : 20211109
<SEC-HEADER>0001453687-21-000155.hdr.sgml : 20211109
<ACCEPTANCE-DATETIME>20211109080036
ACCESSION NUMBER:		0001453687-21-000155
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211109
DATE AS OF CHANGE:		20211109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELECTA BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001453687
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37798
		FILM NUMBER:		211389945

	BUSINESS ADDRESS:	
		STREET 1:		65 GROVE STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-923-1400

	MAIL ADDRESS:	
		STREET 1:		65 GROVE STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>selb-20211109.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:30f74a8f-421a-468c-86c0-3b6ecbc91201,g:039c6c46-87dc-4a4d-8469-a0504021ee10,d:b208aa94bc28435cab855cf63ce7d83c--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>selb-20211109</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY180L2ZyYWc6ZGJlYTIzOGNlZmVhNGNiYTgxYjQ3Nzk4NWUyNTU1NDMvdGFibGU6YmViOTliYzI5MWQ2NDA5ZWI3MmY2YTQyMTNhMTkyNTgvdGFibGVyYW5nZTpiZWI5OWJjMjkxZDY0MDllYjcyZjZhNDIxM2ExOTI1OF8wLTEtMS0xLTI1NDM1_398b2fc2-f8e6-4038-8fb6-c7a0d2b8f727">0001453687</ix:nonNumeric><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY180L2ZyYWc6ZGJlYTIzOGNlZmVhNGNiYTgxYjQ3Nzk4NWUyNTU1NDMvdGFibGU6YmViOTliYzI5MWQ2NDA5ZWI3MmY2YTQyMTNhMTkyNTgvdGFibGVyYW5nZTpiZWI5OWJjMjkxZDY0MDllYjcyZjZhNDIxM2ExOTI1OF8xLTEtMS0xLTI1NDM1_5e0c5dd4-24b8-4789-be6e-d6fa867ae680">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="selb-20211109.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib208aa94bc28435cab855cf63ce7d83c_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjY4_ffddf8b4-b548-46d6-9e63-32de60a945b2">8-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8yMzQ_323cffaa-a9af-427c-a1c7-03152cd7791f">November 9, 2021</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjY5_0651b0d0-25ca-4d66-8876-9894092495ed">SELECTA BIOSCIENCES,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:29.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6ZGQ0MTczYjEwNGM3NDA3ZGFhMDIzMjZkNDMzYTFjZTIvdGFibGVyYW5nZTpkZDQxNzNiMTA0Yzc0MDdkYWEwMjMyNmQ0MzNhMWNlMl8wLTAtMS0xLTI1NDM1_ceb4f089-7981-4465-9312-7dff8c8c0a5c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6ZGQ0MTczYjEwNGM3NDA3ZGFhMDIzMjZkNDMzYTFjZTIvdGFibGVyYW5nZTpkZDQxNzNiMTA0Yzc0MDdkYWEwMjMyNmQ0MzNhMWNlMl8wLTItMS0xLTI1NDM1_a891f0b0-ba71-4a3d-aa3e-6d4a39f8c935">001-37798</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6ZGQ0MTczYjEwNGM3NDA3ZGFhMDIzMjZkNDMzYTFjZTIvdGFibGVyYW5nZTpkZDQxNzNiMTA0Yzc0MDdkYWEwMjMyNmQ0MzNhMWNlMl8wLTQtMS0xLTI1NDM1_bf41b421-b422-4ada-8fc2-ba8c41e5a3c0">26-1622110</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction <br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">   </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjY0_9d47fa8d-acce-4396-972e-55f2c0996b01">65 Grove Street,</ix:nonNumeric> <ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjcw_5ce98eba-6e2a-46d3-95d1-d2f6013eb3eb">Watertown,</ix:nonNumeric> <ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjcx_97e8d685-dff3-417e-a804-ff3c84d26e21">MA</ix:nonNumeric> <ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjcy_f188bcb0-310f-472d-9501-b3c1070472a3">02472</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)(Zip Code)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjY1_4bda761d-d6b5-43f2-aafa-83e19cd30d73">617</ix:nonNumeric>) <ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjcz_509c8047-2264-4756-879f-6e710fd154c3">923-1400</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmQ2ODVhN2RlZmEyNDIzNzhiNjNkMDZmOThhNGVhMmEvdGFibGVyYW5nZToyZDY4NWE3ZGVmYTI0MjM3OGI2M2QwNmY5OGE0ZWEyYV8wLTAtMS0xLTI1NDM1_befd1c98-098b-488f-8477-c00c2cf604cb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmQ2ODVhN2RlZmEyNDIzNzhiNjNkMDZmOThhNGVhMmEvdGFibGVyYW5nZToyZDY4NWE3ZGVmYTI0MjM3OGI2M2QwNmY5OGE0ZWEyYV8yLTAtMS0xLTI1NDM1_d58fcc94-6702-417e-a251-2fe05fff0654">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmQ2ODVhN2RlZmEyNDIzNzhiNjNkMDZmOThhNGVhMmEvdGFibGVyYW5nZToyZDY4NWE3ZGVmYTI0MjM3OGI2M2QwNmY5OGE0ZWEyYV80LTAtMS0xLTI1NDM1_1bb7f06d-99c5-4770-a24d-009e8fe681b4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmQ2ODVhN2RlZmEyNDIzNzhiNjNkMDZmOThhNGVhMmEvdGFibGVyYW5nZToyZDY4NWE3ZGVmYTI0MjM3OGI2M2QwNmY5OGE0ZWEyYV82LTAtMS0xLTI1NDM1_7b6e3126-02dc-4080-97bf-1f99a9769d3c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:39.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmYzNjU1OGM4NDgwNDcwMmJlZjhhZDE5NDRhODkzNDkvdGFibGVyYW5nZToyZjM2NTU4Yzg0ODA0NzAyYmVmOGFkMTk0NGE4OTM0OV8zLTAtMS0xLTI1NDM1_e242a5ea-e35c-4015-b09e-53fe9962e310">Common Stock (Par Value $0.0001)</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmYzNjU1OGM4NDgwNDcwMmJlZjhhZDE5NDRhODkzNDkvdGFibGVyYW5nZToyZjM2NTU4Yzg0ODA0NzAyYmVmOGFkMTk0NGE4OTM0OV8zLTEtMS0xLTI1NDM1_88d57e8d-9cb7-4ebb-a351-5cff5c772d4d">SELB</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmYzNjU1OGM4NDgwNDcwMmJlZjhhZDE5NDRhODkzNDkvdGFibGVyYW5nZToyZjM2NTU4Yzg0ODA0NzAyYmVmOGFkMTk0NGE4OTM0OV8zLTItMS0xLTI1NDM1_7ae67333-2e8e-43ee-886b-ae215522d54f">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjY2_ae61e7ed-3da5-4496-841c-d1a712128aff">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjY3_d48a6d7a-1699-42ff-9622-4cfee51a524d">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.780%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib208aa94bc28435cab855cf63ce7d83c_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, Selecta Biosciences, Inc. announced its financial results for the quarter ended September 30, 2021. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report and on Form 8-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Exhibits</span></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991_earningsrelease.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991_earningsrelease.htm">Press Release issued on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991_earningsrelease.htm">November</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991_earningsrelease.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991_earningsrelease.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991_earningsrelease.htm">, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib208aa94bc28435cab855cf63ce7d83c_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SELECTA BIOSCIENCES,&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 9, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Carsten Brunn, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carsten Brunn, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991_earningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6c76071195b44a40abcec1bb1c517e9c_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="selectalogoa06a.jpg" src="selectalogoa06a.jpg" style="height:74px;margin-bottom:5pt;vertical-align:text-bottom;width:204px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">Reported topline data from SEL-399 (empty AAV8 capsid in combination with ImmTOR)&#59; Selecta intends continued expansion of ImmTOR platform across gene therapy pipeline</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">Continued execution of multiple preclinical programs toward IND</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">Further strengthened leadership team with the appointment of Kevin Tan as CFO</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">As of September 30, 2021, Selecta had approximately $140.0 million in cash, cash equivalents, restricted cash and marketable securities which is expected to provide runway into the second quarter of 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">WATERTOWN, Mass., November 9, 2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> -- </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Selecta Biosciences, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> (NASDAQ&#58; SELB), a biotechnology company leveraging its clinically validated ImmTOR&#8482; platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;The third quarter of 2021 was filled with many significant advancements that further validated the value and breadth of our innovative ImmTOR platform, including important milestones across our pipeline and the establishment of numerous collaborations that will continue to propel us forward in the year ahead,&#8221; said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. &#8220;We recently presented topline data from the empty AAV8 capsid study, SEL-399 in healthy volunteers. We believe this pioneering proof-of-concept study showed for the first time ImmTOR&#8217;s potential to address one of the biggest limitations in gene therapy&#58; preventing the formation of anti-AAV8 neutralizing antibodies after ImmTOR treatment with AAVs and enabling re-dosing of life-saving gene therapies. We are excited to build on these exciting findings, which will inform our clinical development strategy and bring hope to those patients suffering from monogenic disease. We continue to prosecute our clinical pipeline, execute value accretive business development with world class partners and add talent and depth to our leadership team.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Highlights and Anticipated Upcoming Milestones&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Enzyme Therapies&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">SEL-212 for chronic refractory gout&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Enrollment for the Phase 3 DISSOLVE clinical program for the treatment of chronic refractory gout, which was licensed to Sobi, is progressing as planned. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Topline data is expected in the second half of 2022.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">ImmTOR with IgA1 protease for IgA nephropathy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Immunoglobulin A nephropathy (IgAN) is a leading cause of chronic kidney disease (CKD) and renal failure. Current treatments fail to address the root cause of the disease.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Investigational New Drug, or IND, enabling studies are underway. Selecta expects to file an IND in IgA nephropathy in 2022 and will provide additional updates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Gene Therapies&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">First-in-human trial of SEL-399&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In collaboration with AskBio, Selecta initiated the first-in-human, dose-escalation trial of SEL-399, an adeno-associated viral serotype 8 (AAV8) empty vector capsid (EMC-101) containing no DNA combined with ImmTOR. The key objective was to determine the dose regimen of </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ImmTOR to effectively mitigate the formation of antibodies to AAV8 capsids used in gene therapies. Data was released on November 8th 2021. Key findings included&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">No Serious Adverse Events were reported. All treatment-related adverse events were expected for ImmTOR, readily monitorable, and transient</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">At 30 days 6 of 6 or 100% of subjects that received 0.3 mg&#47;kg of ImmTOR exhibited an anti-AAV8 neutralizing antibody titer of 1&#58;25 or less. 4 of 6 or 67% of subjects at this dose had a titer of 1&#58;5 or less</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">At 30 days 6 of 9 or 67% of subjects that received 0.15 mg&#47;kg of ImmTOR exhibited an anti-AAV8 neutralizing antibody titer of 1&#58;25 or less. 2 of 9 or 22% of subjects at this dose had a titer of 1&#58;5 or less</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">At 90 days 2 of 6 subjects in the 0.3 mg&#47;kg cohort were observed to have sustained control of neutralizing antibodies with titers of 1&#58;25 or less</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Consistent with preclinical data, we observed that the single dose ImmTOR cohorts saw delayed formation of neutralizing antibodies eventually reaching similar median levels of neutralizing antibodies to the control group by day 90 </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">While most subjects treated with ImmTOR showed increases in antibody titers by Day 90, preclinical studies in mice and nonhuman primates indicate that if antibodies can be controlled at Day 30, we can maintain control with additional two monthly doses of ImmTOR.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">SEL-302 for methylmalonic acidemia (MMA)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IND filed for SEL-302 (MMA-101 in combination with ImmTOR), for the treatment of MMA, a rare metabolic disease in which the body cannot break down certain proteins and fats.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">IND Filed in Q3 2021, 30-day FDA review period has expired</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">FDA has orally communicated they are still considering certain aspects of the submission related to chemistry, manufacturing and control, or CMC</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Formal FDA decision on IND expected by the end of November.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">SEL-313 for ornithine transcarbamylase deficiency (OTC deficiency)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Selecta&#8217;s proprietary gene therapy product candidate, SEL-313, is being developed to treat OTC deficiency, a rare genetic urea cycle disorder that causes ammonia to accumulate in the blood due to mutations in the OTC gene.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">SEL-313 is currently in preclinical development and a clinical trial application, or CTA, and&#47;or IND filing are expected in 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restoring Self-Tolerance in Autoimmune Diseases&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Selecta continues IND-enabling work on an ImmTOR-based approach to treating primary biliary cholangitis (PBC) and expects to file an IND in PBC in the second half of 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate Updates&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Strategic Collaborations&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Gene Therapies</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)&#58; Strategic licensing agreement to develop next-generation gene therapies in two lysosomal storage disorders. The collaboration leverages Selecta ImmTOR platform to enable redosing of transformative therapies. </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Genovis&#58; Strategic licensing agreement to advance a next-generation IgG protease. This partnership leverages Genovis&#8217; proprietary and differentiated immunoglobulin G (IgG) protease, IdeXork (Xork), and Selecta&#8217;s ImmTOR platform to enable the dosing of transformative gene therapies in patients with pre-existing adeno-associated virus (AAV) immunity and treat certain IgG-mediated autoimmune diseases. Xork shows low crossreactivity to pre-existing antibodies in human sera. The combination of Xork with ImmTOR has the potential to address two of the biggest immunological challenges to gene therapy &#8211; Expanding access to gene therapies by overcoming pre-existing antibodies to AAV and enabling vector re-dosing.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Enzymes</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Ginkgo Bioworks (&#8220;Ginkgo&#8221;)&#58; Partnership to design novel enzymes and proteins with transformative therapeutic potential to advance treatments for orphan and rare diseases. This partnership leverages Ginkgo&#8217;s cell programing platform and Selecta&#8217;s ImmTOR platform to create transformative biologic and enzymatic therapies.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Autoimmune</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Cyrus Biotechnology (&#8220;Cyrus&#8221;)&#58; Established protein engineering collaboration combining Selecta&#8217;s ImmTOR platform with Cyrus&#8217; ability to radically redesign protein therapeutics. The lead program in the collaboration is a proprietary interleukin-2 (IL-2) protein agonist designed to selectively promote expansion of regulatory T cells (Treg) for the treatment of patients with autoimmune diseases and other deleterious immune conditions. The combination of ImmTOR with a Treg-selective IL-2 agonist has the potential to be a best-in-class therapeutic profile.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Leadership Expansion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Kevin Tan was appointed as chief financial officer. Mr. Tan brings deep financial expertise and experience in the gene therapy and rare disease landscape. His impressive track record in capital management and financings, in both the biotech and investment sectors, will be invaluable as Selecta continues to pursue new partnership opportunities and advance multiple assets through the clinic.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Matthew Bartholomae was appointed as General Counsel, Board Secretary and transitioned from his previous role at Selecta as Associate General Counsel, Board Secretary.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Quarter 2021 Financial Results&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Position&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Selecta had $140.0 million in cash, cash equivalents, marketable securities, and restricted cash as of September 30, 2021, which compares to cash, cash equivalents, and restricted cash of $140.1 million as of December 31, 2020. Selecta believes its available cash, cash equivalents, marketable securities, and restricted cash will be sufficient to meet its operating requirements into the second quarter of 2023.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Net cash used in operating activities was $28.9 million for the nine months ended September 30, 2021, as compared to $42.1 million of cash provided by operating activities for the same period in 2020.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Revenue for the third quarter of 2021 was $24.4 million, compared to $4.6 million for the same period in 2020. Revenue of $24.3 million was recognized under the license agreement with Sobi resulting from the shipment of clinical supply and the reimbursement of costs incurred for the Phase 3 DISSOLVE clinical program. The significant revenue increase is the result of the continued enrollment of the Phase 3 DISSOLVE clinical program that was initiated in the third quarter of 2020. Additionally, during the third quarter, Selecta recognized $0.2 million for shipments under the license agreement with Sarepta.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Research and development expenses for the third quarter 2021 were $21.0 million, which compares with $14.0 million for the same period in 2020. During the quarter ended September 30, 2021, there was an increase in expenses incurred for preclinical programs, salaries, headcount, and AskBio collaboration costs.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General and Administrative Expenses&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses for the third quarter 2021 were $5.4 million, which compares with $4.4 million for the same period in 2020. The increase in costs was primarily the result of salaries, professional fees, and stock compensation expenses.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net loss&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the third quarter 2021, Selecta reported net loss of $17.9 million, or net loss per share of $0.16, compared to a net loss of $9.7 million, or net loss per share of $0.09 for the same period in 2020.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conference Call and Webcast Reminder</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Selecta management will host a conference call at 8&#58;30 AM ET today to provide a corporate update and review the company&#8217;s third quarter 2021 financial results. Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10147803. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors &#38; Media section of the company&#8217;s website, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.selectabio.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Selecta Biosciences, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Selecta Biosciences Inc. (NASDAQ&#58; SELB) is a clinical stage biotechnology company leveraging its ImmTOR&#8482; platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body&#8217;s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.selectabio.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selecta Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (&#8220;the Company&#8221;), including without limitation, statements regarding the unique proprietary technology platform of the Company, and the unique proprietary platform of its partners, the potential of ImmTOR to enable re-dosing of AAV gene therapy and to mitigate immunogenicity, the potential of ImmTOR and the Company&#8217;s product pipeline to treat chronic refractory gout, IgA nephropathy, PBC, MMA or OTC, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, the anticipated timing or the outcome of the FDA&#8217;s review of the Company&#8217;s IND and other regulatory filings, the Company&#8217;s ability to conduct those clinical trials and studies, the timing or making of any regulatory filings, the potential treatment applications of product candidates utilizing the ImmTOR platform in areas such as gene therapy, gout and autoimmune disease, the ability of the Company and its partners where applicable to develop gene therapy products using ImmTOR, the novelty of treatment paradigms that the Company is able to develop, whether the observations made in non-human primate study subjects will translate to studies performed with human beings, the potential of any therapies developed by the Company to fulfill unmet medical needs, the Company&#8217;s plan to apply its ImmTOR technology platform to a range of biologics for rare and orphan genetic diseases, the potential of the Company&#8217;s intellectual property to enable repeat administration in gene therapy product candidates and products, the ability to re-dose patients and the potential of ImmTOR to allow for re-dosing, the potential to safely re-dose AAV, the ability to restore transgene expression, the potential of the ImmTOR technology platform generally and the Company&#8217;s ability to grow its strategic partnerships, and other statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;hypothesize,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would,&#8221; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following&#58; the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including the uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human primates, the unproven approach of the Company&#8217;s ImmTOR technology, potential delays in enrollment of patients, undesirable side effects of the Company&#8217;s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the Company&#8217;s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company&#8217;s recurring losses from operations and negative cash flows from operations raise substantial doubt regarding its ability to continue as a going concern, substantial fluctuation in the price of its common stock, and other important factors discussed in the &#8220;Risk Factors&#8221; section of the Company&#8217;s most recent Quarterly Report on Form 10-Q to be filed after this release, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company&#8217;s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selecta Biosciences, Inc. and Subsidiaries</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data and par value)</font></div><div style="margin-bottom:3pt;text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.885%"><tr><td style="width:1.0%"></td><td style="width:67.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,645&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138,685&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,018&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,324&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,224&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,781&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,434&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,768&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,343&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,807&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,395&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use asset, net </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,117&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,948&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167,162&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165,435&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; (deficit) equity </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,593&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,742&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,146&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan payable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,125&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes payable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,828&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,315&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,050&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95,616&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,547&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan payable, net of current portion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,304&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,793&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,873&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,647&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,057&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,746&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,043&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,893&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183,441&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217; (deficit) equity&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $0.0001 par value&#59; 10,000,000 shares authorized&#59; no shares issued and outstanding at September 30, 2021 and December 31, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $0.0001 par value&#59; 200,000,000 shares authorized&#59; 115,443,500 and 108,071,249 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428,371&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391,175&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(442,555)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(404,629)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,559)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,563)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; (deficit) equity </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,731)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,006)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; (deficit) equity </font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167,162&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165,435&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selecta Biosciences, Inc. and Subsidiaries</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div style="margin-bottom:3pt;text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.885%"><tr><td style="width:1.0%"></td><td style="width:42.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant and collaboration revenue</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,427&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,646&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,140&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,646&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,951&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,960&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,418&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,414&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,445&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,420&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,397&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,155&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,396&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,380&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,815&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,569&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,969)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,734)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,675)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48,923)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(461)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(461)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency transaction, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(711)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(365)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,133)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(843)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,779&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,335)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,606)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,066)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,729)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,098)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53,430)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,828)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,828)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,894)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,729)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,926)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53,430)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss)&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive loss</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,896)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,761)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,922)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53,491)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.34)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.54)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#58;</font></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted</font></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,169,949&#160;</font></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,325,788&#160;</font></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,161,622&#160;</font></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,968,359&#160;</font></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For Investors&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bruce Mackle</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LifeSci Advisors, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">+1-929-469-3859</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">bmackle&#64;lifesciadvisors.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For Media&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Brittany Leigh, Ph.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LifeSci Communications, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">+1-646-751-4366</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">bleigh&#64;lifescicomms.com</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>selb-20211109.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:30f74a8f-421a-468c-86c0-3b6ecbc91201,g:039c6c46-87dc-4a4d-8469-a0504021ee10-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:selb="http://www.selectabio.com/20211109" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.selectabio.com/20211109">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="selb-20211109_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="selb-20211109_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageDocument" roleURI="http://www.selectabio.com/role/CoverPageDocument">
        <link:definition>0001001 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>selb-20211109_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:30f74a8f-421a-468c-86c0-3b6ecbc91201,g:039c6c46-87dc-4a4d-8469-a0504021ee10-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_7602af3b-f51b-414e-ae8d-4b179eee9e41_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e02f4dd9-4551-444b-8dc1-ae16d479b079_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ed91f6ef-f8e1-40cd-8652-ae715d155fe5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_f62a4dec-de5d-4829-a057-414ffc033134_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ef529cde-4cd2-45e3-ba64-a46a370bf619_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_912d3ca6-3397-4d4b-8b85-efd5251b2318_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bac69916-146d-48e1-b914-c6cbc506129f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_9aaa251e-d106-44dd-aaa5-58743bc902ea_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_ac6c7d2e-fd93-4672-bc56-4a771347d442_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a49b8e8b-57d7-445f-ada1-c26e9d035910_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_34b18c90-682b-4db9-9f90-7cca96749a0b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_29afdfe5-a3be-41ae-9f3c-54455ae517b9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_319aa89f-e769-45d0-a12b-b0af534927e6_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1ca369a1-b793-40dc-afa2-e2165fec97ba_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e0fa0294-9ecd-4301-a3b2-f1ed6292ed56_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b4cbe630-a972-4b05-a8fd-e9d006272bc8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6a741ebf-1aa3-451e-9dcc-3f8628abcfe4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6b8fd772-96f1-4fa8-8c90-36b9951e8457_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_99d1c110-0738-484a-8ffa-1f572a67d300_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b3f23d9d-c85a-4d86-91dc-b91e8e826b43_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7f265e5d-79a5-4067-9c36-5202b6c33242_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c598153c-eae6-4dc5-b959-ebdfb8f45d2d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9b6e8ae7-ba06-4c76-85f4-696eb4fe39a6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_560c9b5f-8586-4cf1-a9e0-cf9b5a5b7a2a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>selb-20211109_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:30f74a8f-421a-468c-86c0-3b6ecbc91201,g:039c6c46-87dc-4a4d-8469-a0504021ee10-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.selectabio.com/role/CoverPageDocument" xlink:type="simple" xlink:href="selb-20211109.xsd#CoverPageDocument"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1b097395-0554-446e-8102-8e2559f06d4d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_DocumentType_1b097395-0554-446e-8102-8e2559f06d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7428cd2b-03a0-4952-8f84-87713437b199" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_DocumentPeriodEndDate_7428cd2b-03a0-4952-8f84-87713437b199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2011e193-72bf-4cac-901e-7abc582a008e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_EntityRegistrantName_2011e193-72bf-4cac-901e-7abc582a008e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6280982b-3b84-4da0-a18c-fbdf4e220d05" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6280982b-3b84-4da0-a18c-fbdf4e220d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e8b05692-eb29-44cf-91ff-67c1933674e5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_EntityFileNumber_e8b05692-eb29-44cf-91ff-67c1933674e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f1ef1d8e-85c9-4456-924b-efa2a74d5b49" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_EntityTaxIdentificationNumber_f1ef1d8e-85c9-4456-924b-efa2a74d5b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_160a7035-1efb-461f-9aa6-327d7d93f91c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_EntityAddressAddressLine1_160a7035-1efb-461f-9aa6-327d7d93f91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9cd833bd-314a-4930-8403-f244fb07ee79" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_EntityAddressCityOrTown_9cd833bd-314a-4930-8403-f244fb07ee79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3fdc7682-5a85-44d5-aed0-5339695bbdcb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_EntityAddressStateOrProvince_3fdc7682-5a85-44d5-aed0-5339695bbdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bbad067b-210b-46f1-a512-92eda20c0012" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_EntityAddressPostalZipCode_bbad067b-210b-46f1-a512-92eda20c0012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_137cd02a-4b5b-410e-a6d2-315c07005b60" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_CityAreaCode_137cd02a-4b5b-410e-a6d2-315c07005b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b2def548-f1f4-42fa-93b4-50b2b6de08e6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_LocalPhoneNumber_b2def548-f1f4-42fa-93b4-50b2b6de08e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5d3c6879-2108-41c5-a4bd-d3ceeb427afa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_WrittenCommunications_5d3c6879-2108-41c5-a4bd-d3ceeb427afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_206cb851-55d9-4767-859d-45f36a03dc9e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_SolicitingMaterial_206cb851-55d9-4767-859d-45f36a03dc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_9ee99735-25bf-4aac-93e8-0ba6d952b3f0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_PreCommencementTenderOffer_9ee99735-25bf-4aac-93e8-0ba6d952b3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_7591e6d2-04d1-49df-8d99-c8ce0a714772" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_7591e6d2-04d1-49df-8d99-c8ce0a714772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7581943b-d7bf-497f-8718-c92e81b7e204" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_Security12bTitle_7581943b-d7bf-497f-8718-c92e81b7e204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_90fd1f4c-3d69-4a64-9808-223598bd759c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_TradingSymbol_90fd1f4c-3d69-4a64-9808-223598bd759c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d7dc155e-7af3-42bc-b86f-c93c29ac3964" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_SecurityExchangeName_d7dc155e-7af3-42bc-b86f-c93c29ac3964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1abc8ccf-b45d-48ee-8095-2c79fe0f918d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_EntityEmergingGrowthCompany_1abc8ccf-b45d-48ee-8095-2c79fe0f918d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_127b359c-f5ea-41d6-8561-5053122b49d5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_EntityExTransitionPeriod_127b359c-f5ea-41d6-8561-5053122b49d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2ebd29ec-ce6d-4f30-ab86-124218668001" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_EntityCentralIndexKey_2ebd29ec-ce6d-4f30-ab86-124218668001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f1347eed-2773-4bfa-b463-7f4a055fa606" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58b38d58-50fb-400e-9442-a70a42913506" xlink:to="loc_dei_AmendmentFlag_f1347eed-2773-4bfa-b463-7f4a055fa606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>selectalogoa06a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 selectalogoa06a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QA=7)I92!'
M;&%V:6X   60 P "    %   $*:0!  "    %   $+J2D0 "     S4S  "2
MD@ "     S4S  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \Q^,=TZ+I, 8B-C*Y&>"1M _+)_.N^T+3;?2-$M;.T50B1C+
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M)EA*P4E5XYY(QCK42IR@[-&U+%4JT6X.]OO.:^+_ /R3>]_ZZQ?^ABIOA/\
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MI#+<*V]$)*Y5RI(SV.W..V>IZUDX24>9G5'$4YU/9Q=W:_R-NBBBH-PHHHH
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MTH1VMI]Z.PHHHKC/;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY(&164*,Y/561U5L=1IQO%\SZ):GLFEZM8:U9"[TJZCNH-Q7?&<X(Z@^A_\
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M/_(GZA_US'_H0K6C_$CZHY,;_NM3_"_R.+\'^#]/\0:/+=WLURCK.8P(F4#
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M.,))QV:N:97B*E>E)57=Q;5^]@HHHKF/5"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \D^%]G<P>/M6\Z"1/)@DCDW+]UC(N ?<[3^5>MT45C1I
M>RARWN=^/QCQM;VK5M$ON"BBBMC@"BBB@ HHHH *Q_%D,D_A/4(X4+N8LA5'
M)P03^@K8HJH2Y9*78RK4_:TI4WU37WGD/A_Q;?\ A[3WM+>SCE1Y3)F0-D$@
M#M]*U/\ A96J_P#0-@_)O\:]*HKLEB:4G=T_Q/$IY7BZ4%"&):2_N_\ !/,V
M\3^+?$"^1IEH8%8X+V\9'7L78X7Z\5O^$?!@T5A?:@5EOB/E Y6('KSW/O\
M_KKK:*SGB&X\L%RHZ:&6*-15J\W4DMK[+T05P/A*TN(?B%K4DL$B(!*"S*0/
MFD!7GW R/:N^HK*%3DC*/<ZZ^%5:I3J-VY'?U"N9\5>#H?$ ^TV[B"^5=H<_
M=D'8-_C_ #XQTU%3"I*G+FB:XC#T\33=.JKIGF::SXP\,)Y5]:M<P(  TR&1
M5'LZG^9-.;QAXIUK,.DV/E9(!>&$L1]6;@?7BO2J*ZOK,'JX*YY/]EUU[D<1
M)1[=?O\ ^ <3X9\#R6UX-3U]_.N]^]8BV[#==S'N<_X\]NVHHKFJ59597D>G
MA<)2PL.2DO7N_4X[Q+X%34KA]0TF46]XQWLA.$=O7(^Z?Y^W6L8:]XR\/@IJ
M-HUS$H WS1;P/^!KU/U)KTJBMHXEJ/+-<R.&KE<'4=6A-TY/>VS^1YJWC'Q1
MK(,&DV'E$D O#$69?JQX'UQ^-;'A/P;+IUV=4UE_,OB253=NV$]6)[MU_P#K
M]NRHHEB/=<81Y4PHY9:HJN(J.HUM?9?(*P_$OA>U\1VZ^8?)N8Q^[G49X]".
MX_SZYW**YXSE!\T=STZU&G7@Z=173/,XAXS\)@11Q-=VB9VJ%\Z/'X?,H_*G
MCX@Z]<;8;72XFG/&%C=B?H :])HKJ^LPEK.";/'65UJ?NT:\HQ[;_=L>:P>&
M?$GBBZBF\13R06Z\XDP&Q_LH. ?<X_&O2$3RXU0%B% &6.2?J>].HK&K6E4M
M?1([\)@:>%NTVY/=MZL\_O[.Y;XN02+!(4)20,%XVA,$Y^HQ7H%%%%2JZBBK
M;*P\+A%AY5))WYVWZ7,3Q)X8M?$5J!(?)N8Q^[G49(]CZBN.BD\8^$5\H0M=
M6B [1M,L8'KD?,H]CCZ5Z915T\0X1Y)*Z\S#$Y;"M4]M3DX3[KKZ]SS8^/?$
M-^#!I^F()BIR8X7=A[@?XYJ;3O!FJZWJ(O\ Q7,X7C]T6&]QUQQPH^G/TZUZ
M'15O$V7[N*B81RISDGBJKG;ILON&QQI#$L<2*B( JJHP% Z "L3QK$\W@V_6
M)&=MJ'"C)P'4D_D,UNT5S0ERR4NQZM:DJM*5+:Z:^]6.?\#1O%X-LEE1D;YS
MAA@X+L0:Z"BBB<N>3EW"A2]C2C2O>R2^X*\_N+*Y/Q@27R)/+8JX?;P5$0!.
M?J,5Z!154JGLVW;=6,,7A%BHP3=N62?W!7/>)_"5MXAB$BL(+Q%PDN.&]F]O
MY?I70T5,)RA+FB;UZ%/$4W3JJZ9YG'<>,_"JB)H&NK6,$*"GG( .^5^8#V)'
MTI__  G^OWF(;'3(_.(Q\D3N<^H&?\:])HKI^LP>LH)L\C^RZT/=I8B2CVW_
M !/.+/PIX@\0W\5YXDN9((DP0"P$F/\ 94<+T]OH:]'HHK&K6E5:OLCOP>"I
MX1/E;;>[>[./\4^"!J=PVHZ1(+>^X9ESA9".X(Z-[_RZUBKXE\7>'QY6J61G
M12 ))XB>W0.O!_'->E45I'$M1Y9KF1S5LKBZCJT)NG)[VV?R/-3XJ\6:[^ZT
MFQ,*DX\R&(G'L7;@?7BM?POX(:QNAJ>MN)[W=O2/.X(W7<3_ !-_+KSV[.BB
M6)?+RP7*A4LK2J*KB)NI);7V7R"N%U[P',+UM2\.3M%<%RYB+[<,>I1NWT/Y
M]J[JBLJ=65)WB=N*P='%PY:JVV?5>AYL/%?BW1/W>JV/G*&QYDT)'X!EX/ZT
MV3Q'XM\1KY&F6;6\;9!>",K^!=N!^&*]+HK?ZS#?V:O_ %T/-_LNN_<>(ER]
MNOW_ / .8\(>$5T"-KF[82W\J[6*GY8UST'J>F3^7OT]%%<U2I*I+FD>MA\/
M3PU-4Z:LD%%%%0;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>selb-20211109_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="selb-20211109.xsd" xlink:type="simple"/>
    <context id="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY180L2ZyYWc6ZGJlYTIzOGNlZmVhNGNiYTgxYjQ3Nzk4NWUyNTU1NDMvdGFibGU6YmViOTliYzI5MWQ2NDA5ZWI3MmY2YTQyMTNhMTkyNTgvdGFibGVyYW5nZTpiZWI5OWJjMjkxZDY0MDllYjcyZjZhNDIxM2ExOTI1OF8wLTEtMS0xLTI1NDM1_398b2fc2-f8e6-4038-8fb6-c7a0d2b8f727">0001453687</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY180L2ZyYWc6ZGJlYTIzOGNlZmVhNGNiYTgxYjQ3Nzk4NWUyNTU1NDMvdGFibGU6YmViOTliYzI5MWQ2NDA5ZWI3MmY2YTQyMTNhMTkyNTgvdGFibGVyYW5nZTpiZWI5OWJjMjkxZDY0MDllYjcyZjZhNDIxM2ExOTI1OF8xLTEtMS0xLTI1NDM1_5e0c5dd4-24b8-4789-be6e-d6fa867ae680">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjY4_ffddf8b4-b548-46d6-9e63-32de60a945b2">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8yMzQ_323cffaa-a9af-427c-a1c7-03152cd7791f">2021-11-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjY5_0651b0d0-25ca-4d66-8876-9894092495ed">SELECTA BIOSCIENCES,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6ZGQ0MTczYjEwNGM3NDA3ZGFhMDIzMjZkNDMzYTFjZTIvdGFibGVyYW5nZTpkZDQxNzNiMTA0Yzc0MDdkYWEwMjMyNmQ0MzNhMWNlMl8wLTAtMS0xLTI1NDM1_ceb4f089-7981-4465-9312-7dff8c8c0a5c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6ZGQ0MTczYjEwNGM3NDA3ZGFhMDIzMjZkNDMzYTFjZTIvdGFibGVyYW5nZTpkZDQxNzNiMTA0Yzc0MDdkYWEwMjMyNmQ0MzNhMWNlMl8wLTItMS0xLTI1NDM1_a891f0b0-ba71-4a3d-aa3e-6d4a39f8c935">001-37798</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6ZGQ0MTczYjEwNGM3NDA3ZGFhMDIzMjZkNDMzYTFjZTIvdGFibGVyYW5nZTpkZDQxNzNiMTA0Yzc0MDdkYWEwMjMyNmQ0MzNhMWNlMl8wLTQtMS0xLTI1NDM1_bf41b421-b422-4ada-8fc2-ba8c41e5a3c0">26-1622110</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjY0_9d47fa8d-acce-4396-972e-55f2c0996b01">65 Grove Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjcw_5ce98eba-6e2a-46d3-95d1-d2f6013eb3eb">Watertown,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjcx_97e8d685-dff3-417e-a804-ff3c84d26e21">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjcy_f188bcb0-310f-472d-9501-b3c1070472a3">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjY1_4bda761d-d6b5-43f2-aafa-83e19cd30d73">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjcz_509c8047-2264-4756-879f-6e710fd154c3">923-1400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmQ2ODVhN2RlZmEyNDIzNzhiNjNkMDZmOThhNGVhMmEvdGFibGVyYW5nZToyZDY4NWE3ZGVmYTI0MjM3OGI2M2QwNmY5OGE0ZWEyYV8wLTAtMS0xLTI1NDM1_befd1c98-098b-488f-8477-c00c2cf604cb">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmQ2ODVhN2RlZmEyNDIzNzhiNjNkMDZmOThhNGVhMmEvdGFibGVyYW5nZToyZDY4NWE3ZGVmYTI0MjM3OGI2M2QwNmY5OGE0ZWEyYV8yLTAtMS0xLTI1NDM1_d58fcc94-6702-417e-a251-2fe05fff0654">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmQ2ODVhN2RlZmEyNDIzNzhiNjNkMDZmOThhNGVhMmEvdGFibGVyYW5nZToyZDY4NWE3ZGVmYTI0MjM3OGI2M2QwNmY5OGE0ZWEyYV80LTAtMS0xLTI1NDM1_1bb7f06d-99c5-4770-a24d-009e8fe681b4">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmQ2ODVhN2RlZmEyNDIzNzhiNjNkMDZmOThhNGVhMmEvdGFibGVyYW5nZToyZDY4NWE3ZGVmYTI0MjM3OGI2M2QwNmY5OGE0ZWEyYV82LTAtMS0xLTI1NDM1_7b6e3126-02dc-4080-97bf-1f99a9769d3c">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmYzNjU1OGM4NDgwNDcwMmJlZjhhZDE5NDRhODkzNDkvdGFibGVyYW5nZToyZjM2NTU4Yzg0ODA0NzAyYmVmOGFkMTk0NGE4OTM0OV8zLTAtMS0xLTI1NDM1_e242a5ea-e35c-4015-b09e-53fe9962e310">Common Stock (Par Value $0.0001)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmYzNjU1OGM4NDgwNDcwMmJlZjhhZDE5NDRhODkzNDkvdGFibGVyYW5nZToyZjM2NTU4Yzg0ODA0NzAyYmVmOGFkMTk0NGE4OTM0OV8zLTEtMS0xLTI1NDM1_88d57e8d-9cb7-4ebb-a351-5cff5c772d4d">SELB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGFibGU6MmYzNjU1OGM4NDgwNDcwMmJlZjhhZDE5NDRhODkzNDkvdGFibGVyYW5nZToyZjM2NTU4Yzg0ODA0NzAyYmVmOGFkMTk0NGE4OTM0OV8zLTItMS0xLTI1NDM1_7ae67333-2e8e-43ee-886b-ae215522d54f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjY2_ae61e7ed-3da5-4496-841c-d1a712128aff">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109"
      id="id3VybDovL2RvY3MudjEvZG9jOmIyMDhhYTk0YmMyODQzNWNhYjg1NWNmNjNjZTdkODNjL3NlYzpiMjA4YWE5NGJjMjg0MzVjYWI4NTVjZjYzY2U3ZDgzY18xL2ZyYWc6MGQwMTI3Mzg3YWVjNGNjMmI3YzFmNDI1ZDRjN2RlODQvdGV4dHJlZ2lvbjowZDAxMjczODdhZWM0Y2MyYjdjMWY0MjVkNGM3ZGU4NF8xMjY3_d48a6d7a-1699-42ff-9622-4cfee51a524d">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139767556202792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Nov. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  09,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELECTA BIOSCIENCES,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1622110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">65 Grove Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">923-1400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (Par Value $0.0001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SELB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001453687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MNH5/NN_"'-H6%-Q,;>)2Q\3E7J%>M8%8E.[$Q>F[Z/+Y,(5$R-@OS6*%YM,
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ $4!I4Y>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ $4!I4P=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  10&E3$ZZ& .T    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  10&E3F5R<(Q &  "<)P  $P
M        @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !%
M:5/?J&H\5@0  -00   8              " @0P(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  10&E3GZ ;\+$"  #B#   #0
M        @ &8#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !% :5.7BKL<
MP    !,"   +              "  70/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( !% :5/;7P?M.0$  # "   /              "  5T0  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    "  10&E3)!Z;HJT   #X 0  &@
M    @ '#$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M"  10&E399!YDAD!  #/ P  $P              @ &H$@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"  #R$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="selb-20211109.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="selb-20211109.htm">selb-20211109.htm</File>
    <File>exhibit991_earningsrelease.htm</File>
    <File>selb-20211109.xsd</File>
    <File>selb-20211109_lab.xml</File>
    <File>selb-20211109_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "selb-20211109.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "selb-20211109.htm"
     ]
    },
    "labelLink": {
     "local": [
      "selb-20211109_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "selb-20211109_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "selb-20211109.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "selb",
   "nsuri": "http://www.selectabio.com/20211109",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20211109.htm",
      "contextRef": "id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page Document",
     "role": "http://www.selectabio.com/role/CoverPageDocument",
     "shortName": "Cover Page Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20211109.htm",
      "contextRef": "id1b8b3b82c3048109f3227226b1428c3_D20211109-20211109",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.selectabio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001453687-21-000155-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001453687-21-000155-xbrl.zip
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M%<F<(?=$DHJLLH9JA\#BOV)M3RQVS_;T0I:T,\VV]ORUWJPVDX,RYLZPVE[
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M?XDVI4::+=OC]_KD4=@OFSDC+]-$PDQQ/9'00M^&D,61HSO"D3X[EX3I* F
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MP<(CRJ962IDN68U4:>F(JG03RT?'RM/4!5<0%%2KLS"?+J"%]DRWI"LN5:*
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M1\'0="10OF$P?12-)$>C %JK8;S^.-N#^FI7\J+3E*K<@;@<VZ&LIP/<'%[
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MZ^]ROSW4[8YAMNL_YZ'>3<R@1+-#1#.,>*[VWVT=S0[1<"EFV!\=U6@BZ8]
MO2%&TL7[49.[@\]L@7TWHG-RS$?3C?C_"NN'&G >V S#%<N.:Z]Q<QME#4<-
MG2/1>I+:'G=&3&6!3UG@<^"X_DC6Z9A/GYERNJXIN%?[/_2"#J/56YU%4E;U
M'#T2-!]))#H];\927A?0-9(ZJ?>D78IFS>@T5YOWI5OQB3#M&F:S79+B6F%O
M[!?Z;)7C\%&F:9CUO2K+/7R0EA&V)] A=;E,#-WI29.B:=3,O=*E#Q^DO=I!
M98'M-N6$[F*)^ ^Q"6/\\''';!G=>EEJ7HK&'<'J5@P$W;$>B ?AQZ=-C.VZ
MT3!+/76SU=AUH]8J\U">7NN9B<N4!9]+5:^6T397.R/*>L^7\PR91JNYNLJD
M+/=<(S2;+?<LP[-E>/;8P[-9/ZDJUL-[M30!X)4KCO1/6C&MFT:C5K8)VG23
MM\ZVH\K'0I^E_S03_>IV2O_I9I5XH_V(UE@28NFM663@-:/6*FO:-ULRU#4Z
M97!_+5!]YT' M^FG.3#4:0(Y;CM%Z]1@6@=RW'%P<?\ZX:[_Y,%QFE7UB:4_
M>)UP:K=E=!^QZDJ'\ L>1\-H-E>7=1^21WB716_?UBARVX*'^*<N$ML[1-QR
MD=MQ0>80:69I@VMM,.OKPW^M56%"<W:;*E!,[XJ9-6P!@_^I:U=#QN-H) .8
MR59/^#+YQ@E#3*^G5MEQA->8(S08C]CB=8_TU.J+#W>DTK[,39 OG9^3[JH$
M[79!>SPLXD9ZGO0?X0_UVJ,,PC1;H.HTC!8\@E1OUKI&K6,:]6;O,<X18KAK
M7>9A8 N]L;#PJGGWM%WQ9EG8L^'KTTK'WQI@NH9E8D0:;'*\/:/B^,SB8P=L
M]).FQF:]:S0Z90NOS?KC>Z9A=G;;^'G__'I'[ %<6M,;>['+L6VN-OE/FM><
M-9MUH]5J+5P*7O*9GP5HK6FTZ[VM ?0("5%?E"6]<2!&P@]!(6>N#$\["GC6
M!+K<'AJ=(CC;C0.AREV:\2I&]F*-X-8(UQQFQ.;,[!J=AKD,X_:L%^9IG$>M
MUM[9>1P;AW!?N'5D_IS4_HMZ(IY4.]=-@&&OJ?8);84W (N7X;7K+'OYFD\$
MA]<%P)YC[]K=BI\%A6?)I(L(JX7@7]MY>/,:?B0KRXQE"3\2@0;BF]=]?$WO
M9OXM#8!&&R TEB$Y>"\# 98>F'57$\>.1AHZV;?T]FNS5W@?-AM'RU^9W^I:
MJUNVIXTAAEE[##/J=&]O?H79GZ-@QD"&HM(/!+^O\ &L]9*[$SX-\V#P'+^2
MA?D\N)9"90$V'@^&,-@,$Z]^#@/6'V=[4%_(_"&H?Q.NL"+.WCHRM!SA6R(T
MV ??JI(&\RWNAX[M\"";&+B/FRM&J3R7V>@*>FM!]T;ZQ)_(I_,M@G_H1B2,
MR?XQ%@%'LE:ZXDW.U?,QZ^IY'-[Z$]T2>_O@7V_S9]>>:HSK^"P:R1B&L@&Y
MQ ]+(-_&N#5M'0"A_P(X\?,-X%DQ,8*(0;8^)V4 &"X?A^(R^>4J\?4[/NV)
M7KK*3]X:+WH^<"WJ:\UP>KUJM]M"GJ-M'#VQ9D=58D=SHD]]UZQ7FQUSZ=>U
MZO+O5@UK_ORPJ[]KF<URL8>UV/6&/00+W5PKP_61),W>.GM2/&:?\G;O1H$0
M[!,\-PK9.]\6-G*^7+K/)CR2!PJ=S_#)$X!S,LB^1IIQ@3FUWV>-26V;VO!S
M\K,/$7 ;21H^4MB42+41I-IJ&M":C'MY@,<\PB,X^]/GL>V X7E^<%)N/5?B
M[U0BC18DF6YP=&1/+^M?L&Z0?M^VN9FK-7:Y@WK3:-:WT4QA R&'$AUVT+"_
MO94V$"4V'"(VM%J&V=Q&#]<2'0X1'5Z&.1R/$J3#"/XPO9-IBYT\3^'1IZ&&
M8@KU:KVUWVCR582"!]:(U&4;%&17CC$4M11/GIO5NE-]LV;T6MLH%MIP.N'A
M0=9L&+WVO@GKHX!LLVLTS6UT8SIYR#9Z -EM]+=]CDIQ*'+C=^&#?N&2V."V
MY_A.& 64MW24D@/+[+=1$'GR1(@>H%)N;.>.IT9OWWQKQP'9IF&VML\,CL<4
M5440<L$@74-2'%-?NGH;*+*\-F9/3L/L&HWN:LE3GL;+78+6,+J/7()6GL;+
M:;L-H]7NE0TT-^J&75FE?YQX=&8:O?;2NOR2H%_P(!I&I]$L3V+W)]$UVIVE
M+63*@WC!)A==HU=?VN6BE&_KWJW](,(((T;,H6NVC]+]MY4FA2?O2-F^[_T$
M@?I("74)U9_SW6SESJ=C%0I8I<JDSV"%L.+8"4<D(.2 V:)_G*D%V^N!??*T
M=]9L+VT-58*TQ-;] NVVL?5XI,1[&<"?OKYSV9JR*(#!N(6U&G0A\U$*BFVT
MCS]YHMO*%8 G#]6S#;<Z/GF =K>/IL<C'CY@X:0(HR1=X"BEP5G'+'7;#8.T
MT2[YUH9!6C?,QH8;0I= [3:W"M+CD00W(^X/!78+&W!'7Y&%SJ3)$R[#/F1,
M:?5*HV$KJ<>=SNHDEQ*P/YEM8!J-1BF$-ZW7&.WE/=E+B9'+NJ);4E1 ^GA=
M227SVH:P+8&ZC6*4$JK;2)HNW4E/BTGWQ4 &0@L&%O$?)U>$ J9\K?WTFUW*
M_,.-'T3/Z"R_^JX\B!>D""")7K<\B=V?1*MA-!NU,B7WN8&31+H==^C$;!G=
M^E*ZW0OJ/#RHEIE!)<(>%%1?"F&/1SY\%M%I%B-VC&ZOK(';@Y,H39\].8A&
MQ^C52V_ 'IQ$:?IL+NYCY:Y,T\Z^,Q1YY^OV0'T<X)OM.%K.=P*]5HL3WEUU
M.0&W_Q&K0MHCM=9+NV?#LKM>0K2,_.X[4,_VJ1KJ4 3%GWX@8!7_$C89ZEA*
MZ_'@7NAK2@4(D./-=BPEQ8%ZR$X0M"6N'BBN'H_)JYJKYDW>(N_N\YTF^[;S
M97?:K+G%O:8#Y:P^",]<B5@'A5@]H[-<)2_QJL2KYX02EKHD2L0J$>L9D9'>
MCCB65A.3R9*%-0F?-ND4;\ ";1FC>?\R7OARPB.S Y*L#C86@*\C'HCROK]G
M/7J<KL6W/'0L==F?X\:1L,O;L/=E!V>UJKG5^LZ?4I-*1-@%(M26ID>5B'!2
MB+"\:7^)"">%"*VM(L(CRH[MA&.73R]]Z8O5N%,^F7_R> R,[_2'L!F'1?&A
MP)B#)WUE:X1,QE$8@5X)N_F))+O]M Z/?\(3-7*69Q.K92\%WN%$4DVS99CM
MGM%KKG61UQK[WG6B]_$<3:UE-.HMH]-=?:]W>30[H)H&4(UIM.NK6ZZ51_/R
MW8ZZ1J_=-1JM7?.S4E?>C:Z\?PL^E"<)L!>4/0K_VL[#F]?T0Q%0'[_4M)1\
MEXR6H0Q+8$/F5YM_Z_'O-L9I3'..U73F64U=%VHP=;&9#,*\-?-2"UO@@;2P
MMT%L"?:)6_>NV),E?70&XIOEL&O[P0D!7 ;[^/%F3];V7V:E5^]5FNU>I=%M
M]=9?U6"PM54I86,+2P94^',9^R"O\*E7;_H>G>QOO[2;\-Y A);#-5BK8&T?
M".5\$K;#]XMJG"CB_I1]Q$\-]F54O:WNR=H2\KF1GA?[H',@3NP;$;6;[4JG
M95::C79[_XG(Q>>R-(2.JF("FDOL:+1A[K$,'1HS$%B:]R"N)HX=C;06FGU+
MZYBUV2N\'TIT."Q]95[3?)8XW1PFU-;"A+FSS_WL2WL*_XPBSWWS_U!+ P04
M    "  10&E39$,TZ?44  " G@  $0   '-E;&(M,C R,3$Q,#DN:'1M[5WK
M=]JXMO]^_@I=SKWGI&M%X/>#MCDK!9K#3&S:A"8#7[)D2P838S.V28"__F[9
MAH1'6IHF36B9-3,!+$M;TMZ__="6].X_DV& ;EB<^%'XOB26A1+ZS]&[_\'X
MKP]GIZ@>N>,A"U-4BQE)&46W?MI'EY0EU\B+HR&ZC.)K_X9@G+U3BT;3V._U
M4R0)DKCR,*[*@J<KQ/"P(HD$*YKA8D-S!2P[&G,=UQ0E03SL5079=#57T;"A
M4Q<K1*'84#03$T$5%*B7,5$XI%5'$@Q"3,5Q)4.159<XAJJZGB:[3*>&[/)F
M^RGT#GH8)E5_DKXO]=-T5*U4;F]ORQ,G#LI1W*OX8>"'C'>WDL8D3+PH'I(4
MAJ,"G1"P(&%1*MU5@A/F+E4$W\N]Z.:K]8@J%@PLB_-Z*/,7=62$S"N!![S9
M14'^T-],MR0(,C2:I"1TV1V!#Q46Y7L4+JJ''ZZ7WKB5L_*B:9J5[&E1].%"
M?(P7]27^IH) JECYRSH]=_ML2/ JT6M$+/>1/W9(DA>O!B3LO2^Q$'\Y+\$$
M,T*/W@U92A!_'[._Q_[-^U(M"E-@6]R>CN U-__VOI2R25K)Z*T<_>,?_WB7
M^FG CA(6.)@/NB@*YKM*_N.[2EZU$]'IT3OJWZ DG0;L?8GZR2@@TVH8A0P(
M\"=57I#%^4>?4A9F'^&Y#;(3^V[>_B0]8][[DD]%QW!DQY!<65 ,:-&3)4F7
M),T1%<EPY:OZG)0%3244DB%OFOG51@CT36O0G9@$S9"RR9]L6D(^Y57+%U.G
M'MV<2F<W'=D:TT'CIGMB#EK#YM2J]_N=]K70&5K35OWSS+ZT^YU!3X2_0WM@
M#[IM>MVJVX-3V0XZLY%O#8Z5SF5#M4_^&%B#GF#-+@:=RZ9BMR\&W4%GUI&^
MR-UZ;]81#>%4ZDX[EZ[6/?DCZ+2;L]:)'72'%WW[Q/8[[=ZD,_@LV[-KQ;[\
M,K7;7T2[;MW0DX^^<_)%ZPPO_%8[\#NSIFI=?I;L^K':O6S*UK C==J?IU;;
M[EOM:WBO5[QS 6VI8;<]\J&<VKKD]%U/NO6.8-6#H#-PI]U!MV_7FQ-+:DQ:
M[:;8^FC<GK8;J74N3$[A.[0O7LFFX4B>*V'/8!I6!-G AN=HV-6)0"7'\'1)
M+QT)P+F**FN&_JZR-*G/.<?' +F4P^['@/3V<_NMN9VLS:W*!%>E5,&2XAA8
MT0T3.TQCF&H>,32=,,T02D<>"1*V-JV593&.F<=B!F"5;$ ?CDS5) ,UF'B4
MX64U!<QY7TK\X2C@D)7]UH\Y7RP!37F24*BBLEQ'WOY=HP4-232.LV^9/J@6
MS%9PQB.8;5X1R]!D_LVG_+OGLQAE!+&->J[6_'-9+E9?/IK_M%S[",8WHO-O
MH 'BM XVQ1$G"HLBYMB[^FQ!)GV@Z/S)_/N\D<K20,U'=3&,E7NP70%PSQ$^
M&\YOF1578NG^.X56&/HA[C-N^E05J:RKH_3MK4_3?E44A/\K946/WB4C DSE
MQ!6H(/^<U[-6&Z<9D\#OA547!I'%I?SE^7,W"J*X^D\A^^>M!YW$'AGZP;3Z
M[[8_!%:UV2TZBX8D_/=A J8(V"RQ[^4%$W_&JJ(!!&9?;W.B=:B'&P?S3H I
M!F1_L9OM1AV=MX_;C?-EFA<=>CJ:A!6:E(TT(836*'EMXW;>J'TY:[:;C7-T
M;-=1XZ_:?X_MDP:JM2RK>7[>;-DOV(758=[<A4N2]/VPET;A(:J7:V6PZ%7%
M?"4\\*]_BIKP]M6SP<?6F86>T4Z8>V>YE?N29L)D;B98)Y]OK3:H^%E/[EQ>
M#,!,&%C#IMR9?1R"VA:[];.!+9T%T#ZH_ N%_O>/H"L%-\X@NNW6CR?6P)VU
MZK3?O;2$CF1-.P,ZL"Y!_0\NKNT32^Z>?%%L4/G6H*-<>1ZEGN$HV%$54/,:
MU;#)-!G+$F6: !BN.E+IR,!_KBOYYV5C;3>X6-J*BP'*SAIV&YTU/K7.VONA
M^XZA^S2.DS$)4Y1&Z)RY/!B04R[**(J1J![0-_D/D??J.Y/V&>_$./93'VIM
M3-P^&,,,';LIBCPDFK*R5P_?0R8W7/G(G;%1%*?H8/Z=$3!=69(B=L-#;W'V
MF-$WU:?7)7F,"MZ>I%4*S>,A5-GG&@93,L53( 6S<)/.^909VHW<_/Z]E,_4
MFGV^DB79]3Q",#$)#VCJ+B:BJV-!%E7)I;INBE[IR(YNV- !?\H\S$*B>T7T
M ^;4LT?5SEC/3WCL-K7AR>_%U-RB4J\$314=@0I8 L<7*U33L&'H8%89IB*8
MDF*JC'+WYK11:Q^C#\W6>:W9L&N-\\.<AYIVK?Q-'G]M.'S0F!#089P;./S&
M"RY )$')B+D\JD&1'R(_31!H/4#C^,U.B.Z0Q#T_Q&DTJO*0Q*813XD3L'EY
M)XHIBS$0'Y!1PJKS#V_G4>]\"0%G+[TM:G>B-(V&60,W+$Y]EP1%(UE[^>,B
M'&*:94.5N3"G,?Q'YPT7P9)R)N>5E*X_D\RR;LH//A;*XH//OEIM6=4>?OKH
M6G>.6&6K:BO9K.4S![S!N>Y]22[-7Q@12OVP5Y5&$R1NXK<U!HE&/S^^(3R+
M,KEG2O$E0A[$3-DHCFXXKBS;4+FV:89N%(-IEZT1GO/2M6@<IO&T%M'=5#YY
MU+][\EFPVNZL,VC<<@5CUX]!R7SL6_7FS!ITK^VZ->NT/P)]S=6H_W6W_GEB
MSVS?:A\+G9DK6'5Z#33?6@-K:@^AWIG=MR[MP KXBL[Q<M3?98[B"8:)==,0
ML:)H*C9E4<(Z]3S#-5R!J"Y8W2P@MR3>$/@O,+20@>]C[X!Y:^B7 ]^3\_>W
M](*P02\\JD^_O,BN2N1'/V!0.]CK>_';0OR:R^)'#'!Y!$? #M%!_(A,,2$R
MPQJ%SR9(H"FK?.%(Q#)X1\9>_O;RMR)_;3)I%JN(;J85]\*XM3!^7A9&QU-$
M1Y%$#/^30!@IP09/=G"(X2HB4XGL"J4C2<.B)L%T"%^5QJ>V^IY),+_I[65<
M?)"96CS\&J5]%J/!./83ZF?!690MSH(/Z-^WS=[LH6D7YK46#8=^PO,8LUGD
MRASE +*?P)V8P.;9.6H,1T$T97$VA<O* -E1^<TZ+E6R6,0KC\,\>ZAKE<K-
M$=27S9W8+O'@V:V,8TICEB3%GU,@0-Q)"^.'0KW"E4D5W2,&&.FNR[ BFQHV
M=8EA5?4D5S!-S1'$TI&FHI,XNF'H/(T92P]7[83G3&]8FJX:?&S%[>@V_.TF
MR[V]4EUF&LPA6&,2SYRG,C95*F(J>9H@RLR!?WG.#HAM"D/T<M.4&5>M^!/P
MC)]E>/]N<S6Y,G5F4,U0,?4\&2NBSC Q! 7#-]=0J 13"()E';_8''V*DI0$
M77^TLX'&'YJAZ94G&H;C.@*61<'#BBY1D"8!?"79%05=@!^(7#H2)/BP/DE;
MZ\_<W/)#;L14135+"GVI%:YBYOGRUB@&P?1')$!LPMQQZM_P52\PLECRY@"8
M G&N>/;5K5W-Y-ALLQP\H^ARQ7<<,_);"FM'O%(<2G1-I)AJC@IVBB=A0CR"
M#9F)IDME@>H@K)JXMD'CS7,"ZFD$7M.G?A3N<L#XAV!T=J4*I@N*3<<P:@K
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M *I)QH1/11W8A*,H3#Q$M)8L:S5<"EE?0$':2L^]EO]N2<4*!KDI>@6VK /
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M2:TN7;X0*SNU@).@K/2+>L?;DTSK*_I.AQ(FW*\+>C&78:20$ 2@)($ (<1
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MZ:'O<F),&[TW[M2=]%W)]333=PYW7P3.*VJNY?YZ?\7*Q3Q&#&9ZAP]P%C&
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M;6S5FUM/W,@2Q]_S*>:PKZ>9OKJ[4<**PR9'Z+ ;E+#*:E^LOE0/5CPVLDV
M;W_*!G:Y)%D+6\)Y88:>QE7]K]]T5Y7-ZY^OMN7J"S1M45=O=M@NW5E!%>I8
M5)LW.[^?OB-FY^?]5Z]>_XN0/_[SX7CU2QTNME!UJ\,&7 =Q=5ET9ZM/$=K/
MJ]34V]6GNOE<?'&$[ ]_=%B?7S?%YJQ;<<K9XT^;/4&3ELXD(CES1&8F$),%
M2H3/(/A@&:?LWYL]*FS(@LR(T3$0Z60D1F:6.*JHQ L#,#I<M"RJSWO]#^]:
M6.'BJG;X]<W.6=>=[ZW7EY>7NU>^*7?K9K/FE(KUW>R=V^E73^9?BF$VL]:N
MAT__FMH67YN(EV7K/WX]_AC.8.M(4;6=JT)OH"WVVF'PN ZN&S3_1[]6WYS1
M_T;NII%^B#!.!-N]:N/._JO5ZD:.IB[A Z15__K[AZ,')ELH(73.%_5NJ+?K
M?LKZL$8@3MP&[H*-C@\7ZJ[/X<U.6VS/2[@;.VL@X1B4GO019HS:WOQ/3R^R
M_MNC\P9:'!H4.,:!VVOUUJ=Z!U<=5!%NUG]GKZS#@TEEKW[=W/UEZ3R4PV@>
MH<@'"P>^[1H7NEP9+TQ4ABB:/)&4 K%2<N(T=9);)A3-'HK1+Z#%%0S!:B'L
M;NHO:[SPNA>H?S,H-:CTQ-R-2L_S^TZ04YR;,T^M%E81JI0D4F9 #*.<&.!*
MV42S*.,DM^];>^CU_>@>-&%5-Q$:W%SNS+DF/(GT0[!O9ZS/78,7(N&L*/]R
MMM]EYHA55\^@W$U8T-V=%:XZ0=- /+Z)RC<7-ZRLPRT7AIES1/P$FJ*.;ZOX
M"^[)N9;<A,@]H<)1(JU"WY.1N'=J)J30'C>R64+_P.PH!OCR&7B^EB\,P]NJ
M*[KK#[ I>B6J[C>WA1R/3P;,"J*YQT,VN$ L94"T\T$9[B@U,(F%KUD=A8)8
M+@J3E5P$"4>8QS7G=3,(_Q'UA\/ZHNJ:Z\,Z0IYQ0ZU!L(5'G&5$NAW#["OY
MF"1P3B-5,X#Q72=&<2*7SLE\.B\"FW=%";]=;#TT.1A/568Y <\MGH0A$<M2
M(ID.^$40F98P!R-_6QP%A%HZ$,]4<!'1/W571Q&U*E)Q4Z#<+B0Q2"P:3(54
MZ!>B,F*Y] 22XT[+J+R<EE-\U_PH+K*E<S&'MHN Y"!&#$%[^X(%'+"<9115
M$(K@8E":C"'ISF5$<!UUM")9%F8 Y"NF1\&AEP['5$V7!,8AOGW?G-:756Y#
M-$+X2 23#O-G08F15)#$I4R>:@ ]Q[[QQ/ H*,P/ L4S]5P2$D->]+XY:>HO
M114@%RD&G1E.E#,*][RHB(-(B1+"9E9Y'X.?CXM'UD?!87\0.*8HNR1"3NJV
M<^6?Q?F0-GOO(LVT)YS1?NM+C#C%.!Z,$!VG@5+&Y^/C@>UQS2SZ@^#Q?%E?
M&(Y^TSMHP U^,Z%#I!QW/*_0;X92N"SVO6X5J*94^8Q.PN&^M7$ ++B=^6SI
M7CCD_4V1\N2LKN[*)\\C)"4-22QA\<R3(U9XB7IX[K,(U,"TWOMCB^-"O^ N
MYB0)7SC\GYJBZZ ZK+?;B^JV1&IS%47(C+;]EF60WX#GF<0$"(<!O.3:)3>)
M@:^:'0?"@GN8T\5\81H^UF41BJZH-K]B@M,4KLPYS8(WBA&E(A;*.M-8,MM(
MI$HB<U3$8*<ULY_:',?!@GN4$V5\80A.&N@)!DQLA_MS_:W=YGU"/W(+8*W&
MXIBKOA_O^GZ\ $.HQ^/-*NY%FI82?-OV."@6W*><2=9EP7'4MA?0W%^+5I9!
MG^M0&1D6RS$1$ZTEP02@3C.I];0BXI\\& ?*@AN7LTK\T@<*A L\%*\9]Z=%
M5P+Z;IB5PI.H>]2M1M\U,R1@-628U\"IG':</+(X#H<%MRHG2?C"X3]M7/]4
MV\?KK:_+W-(4,2$.1,0,ST"726(-ID2<"V6-C\CUM';U W/C K_@=N3SQ5O(
ME_[M53ASU0:&6_E1Q\"4ZN_=)X$UD0_$FRPAM2)PZX*PV3Q?_/M6QS&PX*[C
M9"D7T6U\NX5F@RC_MZDONS,\W,Y==9TSY_'$"HEXJ3 1-@#$4(M)4- V 4V6
MF6E/RWW'^+@'IQ;?;YPN[#+XN,*]KFJ+7O^;1\%RQK7'C2V0I,!AT1PSK)<R
M+)^H$HQSCUG/'(]!/+4\CHP%-R)GD7016!RB7HTKCS#SO?H?7.<<?.06 @F8
M_1*9!"4.-S["N.3,9)FAE,W Q".SXX!8<'MRNI@O3,,!ED&Q+X7>E6Z3)R:D
M!HB$:XVGGT\.][E,$)VDHTHEETU\-OR!N7'17W!/\OGBS1;UU^LGXAWCP/ZK
MVP_Z'_U_4^R_^C]02P$"% ,4    "  10&E3(81:Z:,J  "]TP$ '@
M        @ $     97AH:6)I=#DY,5]E87)N:6YG<W)E;&5A<V4N:'1M4$L!
M A0#%     @ $4!I4V1#-.GU%   @)X  !$              ( !WRH  '-E
M;&(M,C R,3$Q,#DN:'1M4$L! A0#%     @ $4!I4^+*\:YU @  F@<  !$
M             ( ! T   '-E;&(M,C R,3$Q,#DN>'-D4$L! A0#%     @
M$4!I4W'(5SK4"@  ,&(  !4              ( !IT(  '-E;&(M,C R,3$Q
M,#E?;&%B+GAM;%!+ 0(4 Q0    ( !% :5,94%JCY 8  !LS   5
M      "  :Y-  !S96QB+3(P,C$Q,3 Y7W!R92YX;6Q02P4&      4 !0!0
) 0  Q50

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
